After an apparent accidental early release, Pfizer has revealed phase 1 data showing its investigational candidate, alongside ...

Bayer is committed to advancing treatment in prostate cancer care, showcasing new analyses from its comprehensive clinical trial program for NUBEQA ® (darolutamide), which includes the ARANOTE, ...

Evan Y. Yu, MD, discusses the key efficacy findings from the PEACE-3 study, which assessed the combination of enzalutamide ...

Data highlights PYLARIFY’s ability to detect recurrent prostate cancer in patients with low PSAReal-world evidence of PYLARIFY’s effectiveness in ...

RedHill Biopharma has begun a trial to assess the combination of opaganib and darolutamide for metastatic castrate-resistant ...

Researchers will use a lipidomic biomarker test to select patients with a poor prognosis who may benefit from an investigational combination therapy.

The 80-patient placebo-controlled randomized Phase 2 study will evaluate the efficacy of opaganib in combination with Bayer's darolutamide in men with metastatic castrate-resistant ...

RedHill Biopharma (RDHL) announced the initiation of a Phase 2 clinical study to evaluate the efficacy of its opaganib candidate in combination ...

In a video interview, William K. Oh, MD, director of precision medicine at Yale Cancer Center and Smilow Cancer Hospital discusses the latest breakthroughs in advanced prostate cancer treatment.

In a video interview, William K. Oh, MD, director of precision medicine at Yale Cancer Center and Smilow Cancer Hospital discusses the latest breakthroughs in advanced prostate cancer treatment.

PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. The New England Journal of Medicine, 385(12), 1091–1103.